Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of a Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (ATLAST)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
ApniCure, Inc.
ClinicalTrials.gov Identifier:
NCT01146782
First received: June 15, 2010
Last updated: May 28, 2014
Last verified: May 2014
  Purpose

This is a prospective study of the Attune Sleep Apnea System for the treatment of obstructive sleep apnea. The objective of the study is to demonstrate safety and effectiveness of the Attune Sleep Apnea System to support FDA marketing clearance of the device.


Condition Intervention
Obstructive Sleep Apnea
Device: Attune Sleep Apnea System

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Treatment
Official Title: The ATLAST Trial - A Multicenter, Prospective Study of the Attune Sleep Apnea System for the Treatment of Obstructive Sleep Apnea (OSA)

Resource links provided by NLM:


Further study details as provided by ApniCure, Inc.:

Primary Outcome Measures:
  • Clinical Success Defined as Apnea-hypopnea Index (AHI) Reduction of >50% and Treated AHI<20 [ Time Frame: first treatment night ] [ Designated as safety issue: No ]
    Comparing first treatment night AHI to control/baseline night. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and >30/hr = severe OSA. For each subject, Clinical success was defined as apnea-hypopnea index (AHI) reduction of >50% and treated AHI<20. The number of subjects with clinical success was determined to calculate the primary endpoint as the ratio of the number of subjects with clinical success to the number of subjects.


Secondary Outcome Measures:
  • Adverse Event Rate [ Time Frame: 4 weeks ] [ Designated as safety issue: Yes ]
    Further categorized as serious and non-serious, device-related and non-device-related, unanticipated and anticipated, and based on level of severity. Adverse events will be evaluated during the trial at the following visits during 28-day take-home period: 7-day, 14-day, 21-day, 28-day follow-up, and any unscheduled visits.

  • Last Treatment Night Response (AHI Reduction) [ Time Frame: At completion of 28 day home use. ] [ Designated as safety issue: No ]
    Comparing AHI at the last treatment night to the control/baseline night is reported as the percent change in AHI. AHI is calculated by dividing the number of apnea/hypopnea events by the number of hours of sleep. AHI values are typically characterized as 5-15/hr = mild OSA, 15-30/hr = moderate OSA, and >30/hr = severe OSA. Negative numbers represent a decrease/improvement in AHI, whereas positive numbers represent an increase/no improvement in AHI.

  • Percent Reduction in Oxygen Desaturation Index (ODI) [ Time Frame: First treatment night ] [ Designated as safety issue: No ]
    Comparing first treatment night to control/baseline night reported as percent change. Negative numbers represent a reduction/improvement in ODI, whereas positive numbers represent increases/no improvement in ODI.


Enrollment: 367
Study Start Date: June 2010
Study Completion Date: March 2012
Primary Completion Date: March 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment
Treatment with the Attune Sleep Apnea System
Device: Attune Sleep Apnea System
Console and mouthpiece sleep apnea system

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Subject is between the ages of 18 and 80.
  2. Diagnosis of OSA, based on ODI 10-60 (as assessed per home screening night).
  3. Subject is fluent in English and understands the Study protocol and is willing and able to comply with Study requirements and sign the informed consent form.
  4. BMI < 40.
  5. Subject has a least one molar in each of the four quadrants of the mouth (right upper, right lower, left upper, and left lower).
  6. Subject has proper mouthpiece fit, as assessed by home screening night (See section 8.3).

Exclusion Criteria:

  1. OSA treatment within two weeks prior to Medical/Dental screening visit.
  2. Poor nasal patency as evidenced by Peak Nasal Inspiratory Flow (PNIF) less than 75 l/min (assessed at baseline medical visit). In addition, any ongoing process or condition that limits nasal breathing or indications thereof, including: obligate mouth-breathing, persistent blockage of one or both nostrils resulting in the inability to sleep with the mouth closed, chronic nasal congestion, chronic allergic rhinitis, and intermittent allergic rhinitis that does not respond to non-sedating/non-stimulating medical therapy.
  3. Oral cavity infection or any other oral or dental condition or problem that would limit subject use of the Attune Sleep Apnea System (e.g. dentures, loose tooth/teeth, temporomandibular joint (TMJ) conditions, or any oral or dental condition that the Investigator believes could be exacerbated by the Attune Sleep Apnea System.
  4. Prior use of the Attune Sleep Apnea System.
  5. History of any OSA surgical treatment including uvulopalatopharyngoplasty surgery (UPPP), maxillomandibular advancement surgery (MMA), radio frequency (RF) ablation treatment, palatal stent devices, etc.
  6. Current use or use within the previous 2 weeks of medications or other agents that may affect sleep or PSG, including:

    1. Hypnotics, anxiolytics, anticonvulsants, sedating antihistamines, stimulants, sedating antidepressants or other medications likely to affect neurocognitive function and/or alertness. Patients on stable selective serotonin reuptake inhibitor (SSRI) therapy for > 3 months and who are expected to remain on therapy for the Study duration, may continue SSRI treatment.
    2. Consumption of > 500mg caffeine per day (e.g. > 8 cola-type beverages, > 5 cups of coffee).
    3. Any known illicit drug use or abuse within the past year, or failure to pass drug urine screen test, or alcohol breathalyzer test with result over 0.05% BAL.
    4. Smokers who smoke during the night (interference with PSG).
  7. Any concomitant diagnosed or suspected sleep or chronic neurological disorders, other than OSA, including insomnia, and central sleep apnea.
  8. Currently working nights, rotating night shifts, planned travel across four or more time zones required during Study period, or within two weeks prior to Study enrollment, or sleep schedule not compatible with sleep lab practices.
  9. Potential sleep apnea complications that, in the opinion of the investigator, may affect the health or safety of the participant, including: low blood oxygen, recent near-miss or prior automobile accident due to sleepiness, reported history of severe cardiovascular disease (including NYHA class III or IV heart failure, CAD with angina or MI/stroke in past 6 months, uncontrolled hypertension or hypotension, cardiac arrhythmias), reported respiratory disorders, or use of medication or other treatment which may pose additional risk to the subject or confound the results of the Study.
  10. Female subjects who are pregnant or intend to become pregnant during the study period.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01146782

Locations
United States, Arizona
REM Medical
Phoenix, Arizona, United States, 85037
United States, California
Peninsula Sleep Center
Burlingame, California, United States, 94010
SRI
Menlo Park, California, United States, 94025
United States, Georgia
Sleep Disorders Center of Georgia (SDCG)
Atlanta, Georgia, United States, 30342
United States, South Carolina
SleepMed
Columbia, South Carolina, United States, 29201
United States, Texas
Sleep Medicine Associates of Texas (SMAT)
Dallas, Texas, United States, 75231
Sponsors and Collaborators
ApniCure, Inc.
Investigators
Principal Investigator: Ian Colrain, PhD Stanford Reasearch Institute (SRI)
  More Information

No publications provided

Responsible Party: ApniCure, Inc.
ClinicalTrials.gov Identifier: NCT01146782     History of Changes
Other Study ID Numbers: 10753
Study First Received: June 15, 2010
Results First Received: January 13, 2014
Last Updated: May 28, 2014
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Apnea
Sleep Apnea Syndromes
Sleep Apnea, Obstructive
Sleep Disorders
Sleep Disorders, Intrinsic
Dyssomnias
Nervous System Diseases
Respiration Disorders
Respiratory Tract Diseases
Signs and Symptoms
Signs and Symptoms, Respiratory

ClinicalTrials.gov processed this record on November 19, 2014